Rockwell Medical, Inc. (RMTI): Price and Financial Metrics

Rockwell Medical, Inc. (RMTI)

Today's Latest Price: $2.12 USD

0.04 (1.92%)

Updated May 22 6:55pm

Add RMTI to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

RMTI Stock Summary

  • The ratio of debt to operating expenses for Rockwell Medical Inc is higher than it is for about only 5.36% of US stocks.
  • With a year-over-year growth in debt of -83.33%, Rockwell Medical Inc's debt growth rate surpasses merely 2.42% of about US stocks.
  • Rockwell Medical Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -34.55%, greater than the shareholder yield of just 12.88% of stocks in our set.
  • Stocks that are quantitatively similar to RMTI, based on their financial statements, market capitalization, and price volatility, are LEAF, EKSO, QTRX, LC, and FLDM.
  • Visit RMTI's SEC page to see the company's official filings. To visit the company's web site, go to
RMTI Daily Price Range
RMTI 52-Week Price Range

RMTI Stock Price Chart More Charts

RMTI Price/Volume Stats

Current price $2.12 52-week high $4.90
Prev. close $2.08 52-week low $1.31
Day low $2.05 Volume 968,100
Day high $2.15 Avg. volume 1,177,507
50-day MA $2.19 Dividend yield N/A
200-day MA $2.45 Market Cap 146.43M

Rockwell Medical, Inc. (RMTI) Company Bio

Rockwell Medical is a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. The company was founded in 1995 and is based in Wixom, Michigan.

RMTI Latest News Stream

Event/TimeNews Detail
Loading, please wait...

RMTI Latest Social Stream

Loading social stream, please wait...

View Full RMTI Social Stream

Latest RMTI News From Around the Web

Below are the latest news stories about Rockwell Medical Inc that investors may wish to consider to help them evaluate RMTI as an investment opportunity.

Rockwell Medical (RMTI) Reports Q1 Loss, Tops Revenue Estimates

Rockwell Medical (RMTI) delivered earnings and revenue surprises of 0.00% and 0.96%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 12, 2020

Rockwell Medical, Inc. Provides First Quarter 2020 Financial and Operational Update and Top-line Real-World Triferic Data

-Q1 2020 revenue of $15.9 million- -Received FDA Approval of Triferic® AVNUTM- -Significant expansion of Triferic (ferric pyrophosphate citrate) Dialysate Evaluation Programs.

Yahoo | May 11, 2020

Will Rockwell Medical (RMTI) Report Negative Q1 Earnings? What You Should Know

Rockwell Medical (RMTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research | May 7, 2020

Rockwell Medical (+14%) up on FDA Triferic nod

Rockwell Medical (RMTI +14.3%) is up on 35% higher volume on the heels of FDA approval of IV Triferic (ferric pyrophosphate citrate) for the replacement of

Seeking Alpha | March 27, 2020

The Week Ahead In Biotech: Bristol-Myers, Rockwell Medical Await FDA Decisions, COVID-19 Updates In Focus

Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter. Biotech stocks went on a roller coaster ride in the week ended March 20 amid the market-wide COVID-19 sell-off. Activity remained light amid the cancellation of many medical meetings. The COVID-19 treatment and vaccine development news flow was front and center, as biopharma and diagnostics companies scrambled to capitalize on the need presented by the pandemic. This news flow is likely to continue into the unfolding week, with companies already in the fray providing updates and new entrants making announcements. Related Link: 8 Biotechs With Coronavirus Vaccines In Development The following are other catalysts that could move stocks … Full stor...

Benzinga | March 22, 2020

Read More 'RMTI' Stories Here

RMTI Price Returns

1-mo -6.61%
3-mo -33.33%
6-mo -10.55%
1-year -55.08%
3-year -71.08%
5-year -79.96%
YTD -13.11%
2019 7.96%
2018 -61.17%
2017 -11.15%
2016 -36.04%
2015 -0.39%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9983 seconds.